This Research Topic is part of a series with:
Cannabidiol Treatment in Neurotherapeutic Interventions, Volume IITouted as a cure-all for many health conditions and disorders (e.g., anxiety, depression, schizophrenia, PTSD), cannabidiol (i.e. CBD) has become increasingly ubiquitous in the marketplace. It is important to note that, unlike tetrahydrocannabinol (i.e. THC, the main psychoactive chemical in cannabis), CBD is non-addictive, which makes it an exceptional alternative to THC-derivative cannabinoid drugs. Spurred by the increasing legality of the medical use of the Cannabis sativa plant, a number of medical benefits of CBD have been reported. In the U.S. specifically, CBD (Epidiolex®) is currently marketed for the treatment of Dravet and Lennox-Gastaut syndromes, pediatric epilepsies resistant to anticonvulsants, as well as for spasticity in multiple sclerosis (Sativex®, THC:CBD). Emerging evidence from basic and clinical research suggests a relevant role for CBD in treating a variety of neuropsychiatric disorders, including schizophrenia, depression, PTSD, and drug addiction. However, very little is known regarding the precise neurobiological mechanisms, pharmacokinetics, drug interactions, and clinical consequences of CBD treatment in many of these clinical conditions.
Despite the current CBD “boom” in commercially available products, often at the edge of the law, it remains to be investigated if CBD is an effective medical treatment for a wide range of neuropsychiatric conditions. The aim of this Research Topic is to bring together international experts in the areas of psychiatry, pharmacology, psychology, and neuroscience to provide a deep overview and analysis of scientifically sound evidence that evaluates the use of CBD alone or associated with another drug as a new therapeutic tool for the treatment of neuropsychiatric disorders. All types of articles reporting basic, translational, experimental, or clinical research that includes the most recent and relevant findings in the field of CBD neurotherapeutics are welcome.
This Research Topic is part of a series with:
Cannabidiol Treatment in Neurotherapeutic Interventions, Volume IITouted as a cure-all for many health conditions and disorders (e.g., anxiety, depression, schizophrenia, PTSD), cannabidiol (i.e. CBD) has become increasingly ubiquitous in the marketplace. It is important to note that, unlike tetrahydrocannabinol (i.e. THC, the main psychoactive chemical in cannabis), CBD is non-addictive, which makes it an exceptional alternative to THC-derivative cannabinoid drugs. Spurred by the increasing legality of the medical use of the Cannabis sativa plant, a number of medical benefits of CBD have been reported. In the U.S. specifically, CBD (Epidiolex®) is currently marketed for the treatment of Dravet and Lennox-Gastaut syndromes, pediatric epilepsies resistant to anticonvulsants, as well as for spasticity in multiple sclerosis (Sativex®, THC:CBD). Emerging evidence from basic and clinical research suggests a relevant role for CBD in treating a variety of neuropsychiatric disorders, including schizophrenia, depression, PTSD, and drug addiction. However, very little is known regarding the precise neurobiological mechanisms, pharmacokinetics, drug interactions, and clinical consequences of CBD treatment in many of these clinical conditions.
Despite the current CBD “boom” in commercially available products, often at the edge of the law, it remains to be investigated if CBD is an effective medical treatment for a wide range of neuropsychiatric conditions. The aim of this Research Topic is to bring together international experts in the areas of psychiatry, pharmacology, psychology, and neuroscience to provide a deep overview and analysis of scientifically sound evidence that evaluates the use of CBD alone or associated with another drug as a new therapeutic tool for the treatment of neuropsychiatric disorders. All types of articles reporting basic, translational, experimental, or clinical research that includes the most recent and relevant findings in the field of CBD neurotherapeutics are welcome.
